Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors

Annals of Neurology

Volumn 44, Issue 1, 1998, Pages 35-46

  Liedtke, Wolfgang ^a,d   Cannella, Barbara ^a   Mazzaccaro, Richard J ^a   Clements, John M ^b   Miller, Karen M ^b   Wucherpfennig, Kai W ^c   Gearing, Andrew J H ^b   Raine, Cedric S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b British Biotech Pharmaceuticals Ltd   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; BB 1101; BB 2275; INTERLEUKIN 4; MATRIX METALLOPROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL INFECTION; GENE EXPRESSION; HELPER CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANIMALS; ASTROCYTES; AUTOIMMUNE DISEASES; BASE SEQUENCE; CHI-SQUARE DISTRIBUTION; CLONE CELLS; CYTOKINES; DEMYELINATING DISEASES; DEXAMETHASONE; DOWN-REGULATION; DRUG COMBINATIONS; ENCEPHALITIS; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; METALLOENDOPEPTIDASES; MICE; MICROGLIA; MICROSCOPY, ELECTRON; MULTIPLE SCLEROSIS; OPTIC NERVE; ORGANIC CHEMICALS; PENTOXIFYLLINE; PROTEASE INHIBITORS; RECURRENCE; RNA; SPINAL CORD; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0031902651     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440110     Document Type: Article

References (62)

1. Whitaker JN, Mitchell GW. Clinical features of multiple sclerosis. In: Raine CS, McFarland HF, Tourtellotte WW, eds. Multiple sclerosis: clinical and pathogenetic basis. London: Chapman and Hall, 1997:3-19
2. Raine CS. Biology of disease: the analysis of autoimmune demyelination: its impact on multiple sclerosis. Lab Invest 1984;50:608-635
3. Martin R, McFarland HF, McFarlin D. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10:153-187
4. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996; 85:299-302
5. The IFNB MS Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a mulricenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-666
6. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-1276
7. - T lymphocytes. J Immunol 1981;127:1420-1423
8. Mokhtarian F, McFarlin DE, Raine CS. Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature 1984;309:356-358
9. Dal Canto MC, Melvold RW, Kim BS, Miller SD. Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Microsc Res Tech 1995;32:215-229
10. Wucherpfennig KW, Hafler DA. A review of T cell receptors in multiple sclerosis: clonal expansion and persistence of human T cells specific for an immunodominanr myelin basic protein peptide. Ann NY Acad Sci 1995;756:241-258
11. Raine CS. The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. J Neuroimmunol 1997;77:135-152
12. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989;170:607-612
13. Sharief MK, Hentges R. Association between TNFα and disease progression in patients with mulriple sclerosis. N Engl J Med 1991;325:467-472
14. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991;87:949-954
15. Ruddle NH, Bergman CM, McGrath KM, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental autoimmune encephalomyelitis. J Exp Med 1990; 172:1193-1200
16. Selmaj K, Raine CS, Cross AH. Anti-TNF therapy abrogares autoimmune demyelination. Ann Neurol 1991;30:694-700
17. Chung IY, Norris JG, Benveniste EN. Differential tumor necrosis factor alpha expression by astrocytes from experimental allergic encephalomyelitis-susceptible and -resistant rat strains. J Exp Med 1991:173:801-811
18. Genain CP, Roberts T, Davis RL, et al. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Ptoc Natl Acad Sci USA 1995;92:3601-3605
19. Sommer N, Loeschmann PA, Northoff GH, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1995;1:244-248
20. Probert L, Akassoglu K, Pasparakis M, et al. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system specific expression of tumor necrosis factor a. Proc Natl Acad Sci USA 1995;92:11294-11298
21. Robbins DS, Shirazi Y, Drysdale BE, et al. Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J Immunol 1987;139:2593-2597
22. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23: 339-346
23. Cammer W, Bloom BR, Norton WT, Gordon S. Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: a possible mechanism of inflammatory demyelination. Proc Natl Acad Sci USA 1978;75:1554-1558
24. Cuzner ML, Davison AN, Rudge P. Proteolytic enzyme activity of blood leukocytes and cerebrospinal fluid in multiple sclerosis. Ann Neurol 1978;4:337-344
25. Brosnan CF, Cammer W, Norton WT, Bloom BR. Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis. Nature 1980;285:235-237
26. Gijbels K, Proost P, Masure S, et al. Gelatinase B is present in the cerebrospinal fluid during experimental allergic encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 1993; 36:432-440
27. D'Souza SD, Bonetti B, Balasingam V, et al. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med 1996; 184:2361-2370
28. Mohler KM, Sleath PR, Fitzner JN, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature 1994;370:218-220
29. Gearing AJH, Beckett P, Christodoulou M, et al. Processing of tumor necrosis factor and precursor by metalloproteinases. Nature 1994;370:555-557
30. McGeehan GM, Becherer JD, Bast RC, et al. Regulation of tumor necrosis factor alpha processing by a metalloproteinase inhibitor. Nature 1994;370:558-561
31. Mariani SM, Matiba B, Baeumler C, Krammer PH. Regulation of cell surface Apo-1/Fas (CD 95) ligand expression by metalloproteases. Eur J Immunol 1994;25:2303-2307
32. Racke MK, Bonomo A, Scott DE, et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 1994;180:1961-1966
33. Shaw MK, Lorens JB, Dhawan A, et al. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J Exp Med 1997; 185:1711-1714
34. Cannella B, Gao YL, Brosnan CF, Raine CS. IL-10 fails to abrogate experimental autoimmune encephalomyelitis. J Neurosci Res 1996;45:735-746
35. Raine CS, Mokhtarian F, McFarlin DE. Adoptively transferred chronic relapsing experimental autoimmune encephalomyelitis in the mouse. Neuropathologic analysis. Lab Invest 1984:51: 534-546
36. Liedtke W, Edelmann-W, Bieri PL, et al. GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron 1996;17:607-615
37. Cohen RI, Marmur R, Norton WT, et al. Nerve growth factor and neurotrophin-3 differentially regulate the proliferation and survival of developing rat brain oligodendrocytes. J Neurosci 1996;16:6433-6442
38. Liedtke W, Battistini L, Brosnan CF, Raine CS. A comparison of methods for RNA extraction from lymphocytes for RT-PCR. PCR Methods Appl 1994;4:185-187
39. Lazar JG. Advanced methods in PCR product detection. PCR Methods Appl 1994;4:S1-S14
40. Urrutia R, McNiven MA, Kachar B. Synthesis of RNA probes by the direct in vitro transcription on PCR-generated DNA templates. J Biochem Biophys Methods 1993;26:113-120
41. Chelly J, Kahn A. RT-PCR and mRNA quantitation. In: Mullis KB, Ferre F, Gibbs RA, eds. PCR - polymerase chain reaction. Boston: Birkhaeuser, 1994:97-110
42. Wucherpfennig KW, Sette A, Southwood S, et al. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med 1994;179:279-290
43. Wucherpfennig KW, Zhang J, Witek C, et al. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 1994;152:5581-5592
44. Matyszak MK, Perry VH. Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitots of matrix metalloproteinases. J Neuroimmunol 1996;69:141-149
45. Clements JM, Cossins JA, Wells GMA, et al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumor necrosis factor a inhibitor. J Neuroimmunol 1997; 74:85-94
46. Brosnan CF, Bornstein MB, Bloom BR. The effects of macrophage depletion on the clinical and pathological expression of experimental autoimmune encephalomyelitis. J Immunol 1981; 126:614-620
47. Bonetti B, Raine CS. Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann Neurol 1997;42:74-84
48. Pender MP, Nguyen KB, McCombe PA, Kerr JF. Apoptosis in the nervous system in experimental allergic encephalomyelitis. J Neurol Sci 1991;104:81-87
49. Schmied M, Breitschopf H, Gold R, et al. Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis: evidence for programmed cell death as a mechanism to control inflammation in the brain. Am J Pathol 1993;143:446-452
50. Zipp F, Martin R, Lichtenfels R, et al. Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. J Immunol 1997;159:2108-2115
51. Raine CS. Multiple sclerosis: TNF revisited, with promise. Nat Med 1995;1:211-214
52. Benveniste EN, Benos DJ. TNF-alpha- and IFN-gamma-mediated signal transduction pathways: effects on glial cell gene expression and function. FASEB J 1995;9:1577-1584
53. Ruddle NH. Tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta). Curr Opin Immunol 1992;4:327-332
54. Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. J Clin Invest 1992;94:2177-2182
55. Leppert D, Waubant E, Galardy R, et al. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379-4389
56. Hewson AK, Smith T, Leonard JP, Cuzner ML. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res 1995;44:345-349
57. Norga K, Paemen L, Masure S, et al. Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor D-penicillamine. Inflamm Res 1995;44:529-534
58. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992;41:29-34
59. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996;55:300-309
60. Cuzner ML, Gveric D, Strand C, et al. The expression of tissue type plasminogen activator, matrix metalloproteinase inhibitors and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996;55:1194-1204
61. Leppert D, Waubant E, Buerk MR, et al. Interferon-β1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846-853
62. Stueve O, Dooley NP, Uhm JH, et al. Interferon-1βb decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996;40:853-863